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Epidemiological and experimental evidence suggests 
that increased consumption of soy is associated 
with a reduced risk for prostate cancer. Soy 
isoflavones are thought to be responsible, in part, 
for this anticancer activity.  Soy isoflavones have 
been shown to induce cellular differentiation in a 
number of tissues. However, isoflavone-induced 
differentiation in the prostate has not been 
examined. The present study examined the effects 
of the soy isoflavone, glycitein, on luminal and basal 
cell differentiation in a nontumorigenic prostate 
epithelial cell line (RWPE-1).  Differentiation was 
characterized by inhibition of cellular proliferation, 
cell cycle arrest, and cytokeratin expression.  
Cytokeratins are differentially expressed among 
epithelial cell types with luminal prostate epithelial 
cells expressing cytokeratins 8/18 while basal 
epithelial cells express cytokeratins 5/14.  
Treatment of RWPE-1 cells with the soy isoflavones
genistein, daidzein, equol, and glycitein (0-50µM) 
significantly inhibited cellular proliferation at 50µM 
and glycitein inhibited cellular proliferation at 5 and 
50µM.  Expression cytokeratin 18 was increased 
upon treatment of RWPE-1 cells with with N-(4-
hydroxyphenyl) retinamide (4-HPR, 1µM), while 
glycitein treatment (50µM, 8 d) significantly reduced 
expression of this luminal marker. These data 
suggest that glycitein may induce basal cell 
differentiation in the RWPE-1 cell line.  Maintaining 
the basal cell population within the prostate may 
represent a novel mechanism by which soy 
isoflavones reduce prostate cancer risk. 
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MATERIALS & METHODS
RESULTS and DISCUSSION
INTRODUCTION
To test our hypothesis, the effects soy isoflavones on prostate 
epithelial proliferation, cell cycle distribution and cell differentiation 
were measured using the 3-[4,5-dimethylthiazol-2-yl]-2-,5-
diphenyltetrazolium bromide (MTT) assay, flow cytometric analysis, 
and western analysis, respectively.  
Statistical significance between groups was determined by one-way 
analysis of variance with Tukey’s post-hoc comparisons. Values of 
p<0.05 were considered significant.
Glycitein induces cellular differentiation
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CONCLUSIONS
•Prostate cancer (PCa) is the third leading cause of 
cancer related deaths among American males.
•Prostate carcinogenesis is characterized as a 
continuum of impairment of the homeostatic control 
governing differentiation, proliferation, and 
apoptosis of the prostate epithelium.  
•The prostate epithelium consists of 2 primary 
differentiated cell types, luminal and basal and are 
characterized primarily by their unique cytokeratin
profiles.  
•Loss of luminal cell differentiation and a 
concomitant increase in the proliferation is initially 
observed in low grade prostatic intraepithelial 
neoplasia (PIN).  
•Progression to high grade PIN involves disruption 
and partial loss of the basal cell population with a 
complete loss of this cell population observed in PCa.
•Asian populations have lower PCa incidence and 
mortality but similar rates of incidence of low grade 
PIN when compared to the United States.  The 
reduced incidence of PCa is attributed to increased 
consumption of soy and soy-containing products. 
•This suggests that soy consumption may reduce PCa
incidence by maintaining the basal cell population in 
the prostate epithelium; however, this hypothesis is 
yet to be tested. 
The objective of this study was to identify a 
potential mechanism of preserving the basal cell 
population during PCa progression via 
isoflavone-induced basal cell differentiation of 
an intermediate cell population.
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Conclusion 1:  All isoflavones tested reduced RWPE-1 cell 
proliferation at concentrations of 50µM . Of these, 
glycitein was the only isoflavone that reduced cellular 
proliferation at 5µM. Genistein, but not glycitein was 
cytotoxic at 50µM.
Table 1. Cell cycle analysis of RWPE-1 cells treated 8 days as measured by flow 
cytometry. 4-HPR is a synthetic retinoid known to induce G0/G1 cell cycle arrest and 
was used as a positive control. Data are given as means ± R.S.E.
Figure 1. Progression of prostate cancer.  Loss of 
basal and luminal cell differentiation is 
accompanied by hyperproliferation within the 
luminal compartment of the prostate.  Further 
genetic alterations and complete loss of the basal 
epithelium is characteristic of invasive prostate
HYPOTHESIS
Figure 4. RWPE-1 cells were treated with 1µM 4-HPR, 5 or 50µM glycitein, or 
vehicle alone for 8 days.  4-HPR, a known inducer of luminal differentiation, was 
used as a positive control.  Cytokeratin expression is given as representative 
immunoblot and for quantification. Data given as means ± S.E.M. (n=3)
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Figure 5. RWPE-1 cells were treated with 1µM 4-HPR, 5 or 50µM glycitein, or vehicle 
alone for 8 days.  4-HPR, a known inducer of luminal differentiation, was used as a 
negative control.  Cytokeratin expression is given as representative immunoblot and for 
quantification. Data given as means ± S.E.M. (n=3)
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Taken together these data suggest that glycitein induces basal cell 
differentiation of prostate epithelial cells. Loss of the basal epithelium 
occurs during progression of precancerous lesions in the prostate to 
overt prostate cancer. Preserving the basal cell population may reduce 
the risk of prostate cancer incidence.  
Figure 2. Chemical structures of the major (genistein and 
daidzein), minor (glycitein) soy isoflavones and the daidzein
metabolite (equol). 
Question 1: Do soy isoflavones reduce the proliferation of 
nontumorigenic prostate epithelial cells?
Figure 3.  RWPE-1 cells were treated with 0-50µM genistein, daidzein, equol, or 
glycitein for 8 days.  Cellular proliferation was measured using the MTT assay. 
Data are given as means ± R.S.E.
Conclusion 2: 50µM glycitein was required to reduce S phase 
and increase G2/M phase of the cell cycle as compared to the 
control whereas smaller concentrations of glycitein did not 
effect cell cycle distribution.  
Question 2: We show that glycitein reduces RWPE-1 cellular 
proliferation, does glycitein alter cell cycle distribution?  
Question 3:  Does glycitien induce expression of the 
luminal cell marker, cytokeratin 18?
Conclusion 3:  Unlike 4-HPR, a known inducer of 
cytokeratin 18 expression and luminal differentiation, 
50µM glycitein decreased cytokeratin 18 expression, 
showing that glycitien does not induce luminal 
differentiation.
Question 4:  Does glycitien induce expression of the basal cell 
markers, cytokeratin 5 and p63?
Conclusion 4: Glycitein maintained cytokeratin 5 expression 
and increased expression of p63 suggesting glycitein induces 
basal cell differentiation in the RWPE-1 cell line. The negative 
control, 4-HPR, decreased expression of cytokeratin 5 and p63.
*
*
*
**
We hypothesize that soy isoflavones may 
reduce prostate cancer risk by increasing 
prostate epithelial cell differentiation.
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